• Publications:
• Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial
• Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer
• Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7-IFCT-1402): a prospective multicentre, open-label, randomised, controlled trial
• Synopsis: RTEP7_-_Synopsis_FR_V9_20190419.pdf